Company Initiatives - The company’s board approved the issuance of H-shares and plans for listing on the Hong Kong Stock Exchange, with a shareholder meeting scheduled for early 2026 to discuss this initiative, marking a key step in its internationalization strategy [2] - The company has changed its stock name from "福瑞股份" to "福瑞医科" to reflect its long-term focus on medical technology [5] Regulatory Situation - In December 2025, the company received a warning letter from the Inner Mongolia Securities Regulatory Bureau due to inadequate internal controls and irregular revenue accounting related to its overseas subsidiaries, and submitted a rectification report by the end of the month [3] Industry Policy and Environment - The revised Drug Administration Law Implementation Regulations will take effect on May 15, 2026, emphasizing innovation in drug development and clinical value, which is expected to benefit the demand for the company’s FibroScan series products [4] Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.101 billion yuan, a year-on-year increase of 12.37%, and a net profit of 112 million yuan, up 9.69% from the previous year [6] - As of February 10, 2026, the company’s total market capitalization was approximately 18.347 billion yuan, with a stock price increase of 5.16% on that day, and it has attracted holdings from multiple public funds [6]

Group 1 - The company's revenue showed steady growth, with a year-on-year increase of over 20% in net profit attributable to shareholders after excluding stock payment and exchange rate impacts [1] - In the first half of 2025, the company achieved revenue of 713 million yuan (+11.02%) and a net profit attributable to shareholders of 52 million yuan (-31.09%) [1] - The second quarter of 2025 saw a revenue of 383 million yuan (+19.76%) and a net profit attributable to shareholders of 23 million yuan (-28.63%) [1] Group 2 - Revenue from pharmaceutical and medical services slightly increased to 231 million yuan (+5.62%), contributing 36 million yuan to net profit [2] - The medical device business performed well, generating revenue of 480 million yuan (+13.80%), with equipment sales accounting for 253 million yuan (52.5%) [2] - The gross profit margin slightly decreased to 75.26% (-1.03pp), primarily due to changes in business structure [2] Group 3 - The recent FDA approval of the MASH drug is expected to drive demand for non-invasive testing [3] - The company has expanded its FibroScan product line in over 100 countries, with strong technical barriers and international competitiveness [3] - Revenue forecasts for 2025-2027 are projected at 1.63 billion, 1.92 billion, and 2.27 billion yuan, with year-on-year growth rates of 21%, 18%, and 18% respectively [3]